Armata Pharmaceuticals Inc (ARMP)
Official siteHEALTHCARE • BIOTECHNOLOGY • AMEX
Market Cap: $143.94M
Last updated: Nov 17, 2026 at 11:03 AM ET
Armata Pharmaceuticals Inc (ARMP) Financials: Revenue, Profit and Cash Flow
Armata Pharmaceuticals reported revenue of $4.90M for the fiscal year ended Dec 31, 2025, down 5.2% from the year before. That year, net income was -$173.80M with a net margin of -3544.0%, operating cash flow was -$25.76M and free cash flow was -$26.30M. The quarter ended Sep 30, 2026 had revenue of $3.17M and net income of $54.86M.
Revenue and Margins
Over the 9 years to Dec 2025, revenue grew from $260.00K, a compound annual rate of 38.6%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $4.90M | -5.2% | 100.0% | -747.0% | -3544.0% |
| Dec 2024 | $5.17M | +14.2% | 100.0% | -820.2% | -365.6% |
| Dec 2023 | $4.53M | -17.8% | 100.0% | -902.8% | -1524.5% |
| Dec 2022 | $5.51M | +23.1% | 100.0% | -670.8% | -670.2% |
| Dec 2021 | $4.47M | +443.6% | 100.0% | -532.5% | -517.5% |
| Dec 2020 | $823.00K | N/A | 100.0% | -2623.0% | -2695.1% |
| Dec 2019 | $0 | N/A | N/A | N/A | N/A |
| Dec 2018 | $0 | -100.0% | N/A | N/A | N/A |
| Dec 2017 | $115.00K | -55.8% | 100.0% | -14048.7% | -11163.5% |
| Dec 2016 | $260.00K | N/A | 100.0% | -8991.5% | -7245.4% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.90M | $5.17M | $4.53M | $5.51M | $4.47M | $823.00K | $0 | $0 | $115.00K | $260.00K |
| Gross profit | $4.90M | $5.17M | $4.53M | $5.51M | $4.47M | $823.00K | $0 | $0 | $115.00K | $260.00K |
| Research and development | $23.72M | $34.43M | $33.77M | $35.02M | $20.02M | $14.44M | $9.82M | $15.14M | $2.88M | $5.68M |
| Operating income | -$36.63M | -$42.44M | -$40.89M | -$36.95M | -$23.82M | -$21.59M | -$19.75M | -$17.66M | -$16.16M | -$23.38M |
| Net income | -$173.80M | -$18.92M | -$69.05M | -$36.92M | -$23.16M | -$22.18M | -$19.48M | -$16.70M | -$12.84M | -$18.84M |
| EBITDA | N/A | -$19.76M | N/A | -$36.05M | -$21.93M | -$20.47M | -$17.29M | -$14.50M | -$13.78M | -$19.02M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $3.17M | $2.51M | $789.00K | $1.08M | $1.16M | $2.17M | $491.00K | $1.24M | $2.97M | $0 | $966.00K | $1.53M |
| Gross profit | $3.17M | $2.51M | $789.00K | $1.08M | $1.16M | $2.17M | $491.00K | $1.24M | $2.97M | $0 | $966.00K | $1.53M |
| Operating income | -$7.38M | -$10.31M | -$8.79M | -$13.82M | -$7.78M | -$6.84M | -$8.19M | -$10.54M | -$9.76M | -$11.91M | -$10.23M | -$9.58M |
| Net income | $54.86M | $74.14M | -$115.35M | -$124.30M | -$26.68M | -$16.30M | -$6.53M | $2.60M | -$5.48M | $8.99M | -$25.02M | -$19.85M |
Balance Sheet
As of Dec 2025, total debt of $256.92M exceeded cash and equivalents by $248.23M. Shareholder equity was negative, at -$218.60M, as total liabilities of $295.48M exceeded total assets of $76.88M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $76.88M | $86.44M | $98.36M | $95.83M | $69.77M | $39.52M | $25.45M | $14.54M | $11.14M | $18.15M |
| Current assets | $10.67M | $11.31M | $19.15M | $27.05M | $14.99M | $10.85M | $6.66M | $10.36M | $5.38M | $6.31M |
| Cash and equivalents | $8.69M | $9.29M | $13.52M | $14.85M | $10.29M | $9.65M | $6.03M | $9.66M | $5.13M | $5.71M |
| Total liabilities | $295.48M | $134.46M | $130.43M | $59.75M | $44.37M | $20.66M | $10.86M | $6.85M | $3.41M | $8.43M |
| Short-term debt | $0 | $38.95M | $0 | $17.01M | $3.02M | $1.94M | $970.00K | $970.00K | $0 | $803.00K |
| Long-term debt | $256.92M | $55.44M | $82.31M | $0 | N/A | N/A | N/A | N/A | N/A | N/A |
| Shareholder equity | -$218.60M | -$48.02M | -$32.06M | $36.08M | $25.40M | $18.86M | $14.59M | $7.69M | $7.73M | $9.72M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $84.48M | $89.95M | $69.80M | $76.88M | $89.52M | $80.79M | $87.25M | $86.44M | $98.24M | $108.31M | $120.36M | $98.36M |
| Total liabilities | $258.61M | $321.12M | $381.39M | $295.48M | $185.10M | $150.29M | $141.03M | $134.46M | $149.21M | $154.41M | $176.87M | $130.43M |
| Cash and equivalents | $18.32M | $23.95M | $4.75M | $8.69M | $14.76M | $4.33M | $11.69M | $9.29M | $17.14M | $26.41M | $37.86M | $13.52M |
| Shareholder equity | -$174.13M | -$231.17M | -$311.59M | -$218.60M | -$95.59M | -$69.50M | -$53.78M | -$48.02M | -$50.97M | -$46.10M | -$56.51M | -$32.06M |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$25.76M | -$37.55M | -$47.42M | -$32.48M | -$23.57M | -$18.27M | -$15.58M | -$10.63M | -$9.19M | -$10.61M |
| Capital expenditures | $542.00K | $1.88M | $8.14M | $2.21M | $1.30M | $824.00K | $224.00K | $875.00K | $58.00K | $279.00K |
| Free cash flow | -$26.30M | -$39.43M | -$55.57M | -$34.69M | -$24.88M | -$19.09M | -$15.81M | -$11.50M | -$9.25M | -$10.88M |
| Dividends paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $0 | $80.00K |
| Investing cash flow | -$542.00K | -$1.88M | -$8.13M | -$2.21M | -$1.30M | -$824.00K | $2.88M | $8.81M | -$58.00K | -$279.00K |
| Financing cash flow | $25.61M | $34.96M | $53.99M | $44.02M | $25.52M | $23.21M | $8.97M | $0 | $8.67M | $7.23M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$5.52M | -$8.67M | -$5.78M | -$6.67M | -$4.30M | -$7.21M | -$7.58M | -$7.93M | -$8.86M | -$10.18M | -$10.58M | -$8.11M |
| Capital expenditures | $91.00K | $17.00K | $63.00K | $52.00K | $242.00K | $149.00K | $99.00K | $77.00K | $340.00K | $1.37M | $250.00K | $2.40M |
| Free cash flow | -$5.61M | -$8.68M | -$5.84M | -$6.73M | -$4.54M | -$7.36M | -$7.68M | -$8.00M | -$9.20M | -$11.54M | -$10.83M | -$10.51M |
Frequently Asked Questions About ARMP
What is Armata Pharmaceuticals' annual revenue?
Armata Pharmaceuticals reported revenue of $4.90M for the fiscal year ended Dec 31, 2025.
How fast is Armata Pharmaceuticals' revenue growing?
Revenue was down 5.2% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was -3.8%.
Is Armata Pharmaceuticals profitable?
No. Armata Pharmaceuticals reported net income of -$173.80M for the fiscal year ended Dec 31, 2025, with a net margin of -3544.0%.
How much free cash flow does ARMP generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$25.76M minus capital expenditures of $542.00K produced free cash flow of -$26.30M.
How much debt does Armata Pharmaceuticals have?
The balance sheet dated Dec 31, 2025 reported long-term debt of $256.92M, short-term debt of $0 and cash and equivalents of $8.69M.
ARMP pages: Overview, Earnings, Forecast, Financials, Competitors